Excellent
Fully Aligned
Patient Risk:
Low
Summary
The provided claim about the boxed warning for increased suicidal thoughts and behaviors in pediatric and young adult patients, including the need for close monitoring and the pediatric-use limitation, is fully supported by the supplied label excerpts.
Category Scores
Accurate Statements
Antidepressants (including REMERON/REMERONSolTab) increase the risk of suicidal thoughts and behaviors in pediatric and young adult patients (Boxed Warning).
BOXED WARNING — SUICIDAL THOUGHTS AND BEHAVIORS
Patients should be closely monitored for clinical worsening and emergence of suicidal thoughts and behaviors, including during initial months and times of dosage changes (Warnings and Precautions 5.1).
5.1 Suicidal Thoughts and Behaviors in Adolescents and Young Adults
REMERON/REMERONSolTab is not approved for pediatric patients.
BOXED WARNING — SUICIDAL THOUGHTS AND BEHAVIORS ("not approved for use in pediatric patients")
Safety and effectiveness of REMERON/REMERONSolTab have not been established in pediatric patients with MDD, and antidepressants increased the risk of suicidal thoughts and behaviors in pediatric patients.
8.4 Pediatric Use
The claim is explicitly supported by the label excerpts provided.
BOXED WARNING; 5.1; 8.4
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
No off-label or unsafe guidance is added; the content evaluated is limited to label-supported boxed-warning and monitoring statements for suicidality.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Primary Issue
Suggested Improvement